(Q40390746)

20 September 2017

title

A vaccine against S. pyogenes: design and experimental immune response (English)

1 reference

20 September 2017

1 reference

L Guilherme

1

1 reference

20 September 2017

E Postol

2

1 reference

20 September 2017

S Freschi de Barros

3

1 reference

20 September 2017

F Higa

4

1 reference

20 September 2017

R Alencar

5

1 reference

20 September 2017

M Lastre

6

1 reference

20 September 2017

C Zayas

7

1 reference

20 September 2017

C R Puschel

8

1 reference

20 September 2017

W R Silva

9

1 reference

20 September 2017

L C Sa-Rocha

10

1 reference

20 September 2017

V M Sa-Rocha

11

1 reference

20 September 2017

O Pérez

12

1 reference

20 September 2017

J Kalil

13

1 reference

20 September 2017

language of work or name

1 reference

4 May 2009

1 reference

20 September 2017

1 reference

20 September 2017

volume

49

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

316-321

1 reference

The global burden of group A streptococcal diseases

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Immunogenicity of a 26-valent group A streptococcal vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Progress towards developing a vaccine for group A streptococcus based on the M protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Towards a vaccine against rheumatic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Enhancement of soluble protein expression through the use of fusion tags

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Current status of group A streptococcal vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

Rheumatic fever and rheumatic heart disease: genetics and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.024

10.1016/J.YMETH.2009.03.024

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference